Mistral Pharma Inc.
TSX VENTURE : MIP

Mistral Pharma Inc.

August 24, 2005 09:34 ET

Mistral Pharma Starts Pilot Pharmacokinetic Study of First Branded Product

MONTREAL, QUEBEC--(CCNMatthews - Aug. 24, 2005) - Mistral Pharma Inc. (TSX Venture:MIP) announced today that it has initiated a pilot pharmacokinetic study for MIST-B01, its first branded product. MIST-B01 is a once-a-day controlled-delivery formulation of a widely prescribed drug which is commonly taken twice daily and is already approved around the world for numerous indications. Results from this study are expected in Q4 2005.

"We are looking forward to get the results of this first study on our branded product" said Mr. Bertrand F. Bolduc, Mistral's President & CEO. "If the results of this study are positive, Mistral will be looking actively for a commercial partner to pursue the development of the product" he added.

About Mistral Pharma Inc.

Mistral Pharma is an emerging oral drug delivery company which develops generic and branded controlled-delivery products using its PROCISE™, SAVIT™ and CHRONOP™ geometry surface area technologies. These technologies offer many competitive advantages including flexible and fast development, competitive cost of goods and the use of "generally recognized as safe" excipients. Additional information about Mistral Pharma can be obtained on Mistral Pharma's website at www.mistralpharma.com.

Forward-looking Statements

Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of Mistral Pharma. These statements are based on assumptions and uncertainties as well as on management's best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Mistral Pharma's products, the impact of price pressures exerted by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

Contact Information

  • Mistral Pharma Inc.
    Bertrand F. Bolduc, B.Pharm., MBA
    President and Chief Executive Officer
    (514) 920-0909 ext. 24
    bbolduc@mistralpharma.com
    or
    Mistral Pharma Inc.
    Alain Provencher, CA
    Vice President and Chief Financial Officer
    (514) 920-0909 ext. 22
    aprovencher@mistralpharma.com